Early Recognition and Management of Posterior Reversible Encephalopathy Syndrome: A Newly Recognized Complication in Patients Receiving Tyrosine Kinase Inhibitors.
Przybylyski, Ashley BSN, RN, OCN(R); Esper, Peg DNP, ANP-BC, AOCN(R)
[Article] Clinical Journal of Oncology Nursing. 20(3):305-308, June 2016.

(Format: HTML, PDF)

Background: Adult patients with cancer receiving antineoplastic, targeted, and other immunosuppressive therapies are at risk for severe side effects. Studies link posterior reversible encephalopathy syndrome (PRES) with immunosuppressants used for patients undergoing transplantation, as well as select tyrosine kinase inhibitors (TKIs) and other targeted therapies used in patients with cancer. PRES is a reversible condition with early recognition and management; however, permanent neurologic toxicities have been reported.

(C) 2016 Oncology Nursing Society